Targeted Oncology
Targeted Oncology
Targeted Oncology

An Overview of the GeparSepto Trial in Luminal, Triple-Negative, and HER2+ Breast Cancer

Sibylle Loibl, MD, PhD
Published Online:3:27 PM, Wed January 4, 2017

Sibylle Loibl, MD, PhD, co-chair of the German Breast Group and associate professor at the University of Frankfurt, discusses the most recent subanalysis of the GeparSepto trial in luminal, triple-negative, and HER2+ breast cancer, which investigated if the exchange of nab-paclitaxel instead of paclitaxel followed by epirubicin would lead to an increased pathological complete remission rate.
Publications